A Phase 2 interventional study of Bupivacaine-HCl and Lidocaine in COVID -19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 24th largest by planned enrollment of the 156 interventional ones that give a count, is one of 13 that started in 2026, is one of 48 in phase 2, reaches primary completion later than 74 of the 84 other live ones, and was the 195th registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Stephanie B. Seminara, MD · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 54 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 272 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 53 across the 156 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 195 have an industry lead sponsor. The 10 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
National Institute of Allergy and Infectious Diseases (NIAID) has 2 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
30 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 30 to your calendar (.ics) → With an account.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (SGB or Sham) administered to adults with Long COVID (Figure 1) followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 at Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. Follow-up visits at weeks 12 and 26 allow for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures.
This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (Stellate Ganglion Block (SGB) or Sham) administered to adults with Long COVID followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 on Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. The inclusion of follow-up visits at weeks 12 and 26 allows for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures. The secondary objectives are 1) To compare the change in fatigue severity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 2) To compare the change in attention and working memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 3) To compare the change in processing speed and executive function from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 4) To compare the change in verbal fluency from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 5) To compare the change in learning and memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 6) To compare the change in orthostatic intolerance symptoms from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 7) To compare the change in functional capacity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 8) To evaluate safety in participants randomized to a series of two sets of bilateral SGB or sham Study Procedures.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's planned enrollment of 272 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of SARS-CoV-2 infection*a-d
Clinical evidence of Long COVID*a and Long COVID symptoms that cannot be attributed to another cause upon investigator review of medical history and evaluation prior to study entry. *b
Has a substantial reduction or impairment in ability to engage in pre-illness levels of activity (occupational, educational, social, or personal life) following COVID-19 illness.*a
a. Based on symptom-specific criteria.
Presents at least two of the primary symptoms of interest*a,f that cannot be explained by an alternative diagnosis in the judgment of a site investigator.
Acceptable clinical screening laboratory evaluations.*a,b must be \<1.3 and must be >100,000 per microliter. Other screening laboratory evaluations must be within normal reference ranges or Grade 1 per the DAIDS Table with no clinical significance (NCS) per investigator's discretion.*c
Able to understand and agree to comply with all planned study activities*a and be available for all study visits in the randomized controlled portion of the study.
Agrees to maintain*a,b non-study medications, vitamins, and supplements at current doses for the duration of the randomized controlled portion of the trial.*c
Agrees to maintain non-pharmacological Long COVID therapies (e.g., vagal nerve stimulation, acupuncture) consistent*a for the duration of the randomized controlled portion of the trial.
a. Except as instructed by their treating clinician.
Exclusion Criteria:
to SGB*a,b
History of major surgery,*a myocardial infarction, or cerebrovascular events*b \<=365 days of randomization.
Initiation/discontinuation of medications*a that could affect autonomic function, cardiovascular function, participant safety, or assessment of study outcomes \</= 30 days of randomization.*b,c
Initiation \</= 30 days of randomization or planned initiation during the randomized controlled portion of the trial of non-pharmacologic autonomic interventions.*a
a. Excluded interventions include vagal nerve stimulation, autonomic neuromodulation, acupuncture, or additional sympathetic or autonomic blocks that could increase procedural risk or confound safety assessment.
Has recent active (received chemotherapy or radiotherapy in the 12 months prior to informed randomization) or active malignancy at informed randomization.*a
a. Individuals with non-melanoma skin carcinoma (basal or squamous cell skin cancer), or low-grade cervical squamous intraepithelial lesions, which are considered cured and not requiring ongoing therapy, may be enrolled at the discretion of the investigator.
Diagnosed in the 3 months prior to randomization with a new medical condition,*a other than Long COVID, causing new or worsening fatigue that is unresolved at time of randomization.
a. Medical conditions that could cause new or worsening fatigue include but are not limited to iron deficiency with or without anemia, hypothyroidism, infectious mononucleosis (Epstein-Barr Virus or cytomegalovirus infection), celiac disease, type 1 diabetes mellitus, adrenal insufficiency, cardiac disease (e.g., myocarditis, arrythmia, or cardiomyopathy), metabolic disease, renal disease, or a primary sleep disorder (e.g., obstructive sleep apnea, restless legs syndrome, narcolepsy, or parasomnia).
Participants with clinically significant cardiac conduction disease.*a,b
Clinically significant findings*a at baseline that may increase procedural risk.
a. Including but not limited to: interval (QTc) >480 milliseconds (ms); newly identified atrial fibrillation or flutter, sustained supraventricular tachycardia, or ventricular arrhythmia; second-degree Mobitz II or third-degree atrioventricular block; ventricular pre-excitation, including Wolff-Parkinson-White pattern; Brugada pattern or another finding associated with clinically important ventricular arrhythmia; evidence of acute myocardial ischemia; or any other ECG abnormality considered clinically significant by the investigator or proceduralist.
Physical conditions*a that obscure relevant sonoanatomy, alter the anticipated needle trajectory, or otherwise increase the risk of SGB.*b
Any other circumstance, including medical conditions,*a,b medication use, or other factors that pose a safety risk*c for or interfere with the reliable assessment of trial endpoints.*d
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive paired bilateral SGB administered under ultrasound guidance at the anatomical target of cervical vertebrae C6-C7. A skin wheal of approximately 0.5-3 mL buffered plain 1% lidocaine hydrochloride injection will be placed at the needle entry site. A 21- to 30-gauge block needle will be inserted and advanced to the tissue plane containing the cervical sympathetic chain under real-time ultrasound guidance to deliver 10 mL of preservative-free plain 0.5% bupivacaine hydrochloride injection. N = 136
Drug: Bupivacaine-HCl · Drug: Lidocaine
Participants will receive bilateral sham injections administered on the same schedule as the active arm. A skin wheal of 0.5-3 mL buffered plain 1% lidocaine hydrochloride will be placed at the needle entry site. To simulate the active SGB procedure, a 21- to 30-gauge needle will be inserted only subcutaneously and with no injected medication. N = 136
Drug: Lidocaine
Bupivacaine hydrochloride injection (without epinephrine) is a long-acting amide-type local anesthetic commonly used for the production of local or regional anesthesia and analgesia in a variety of clinical settings, including surgical, obstetrical, and diagnostic procedures. It is typically administered via local infiltration, peripheral nerve block, or epidural or spinal routes in sterile isotonic solution formulations.
Lidocaine is a local anesthetic of the amide group. Intradermal lidocaine hydrochloride injection is a local anesthetic administered into the superficial layers of the skin. It is commonly used prior to minor procedures including the formation of an intradermal skin wheal. When administered intradermally, lidocaine hydrochloride produces localized numbness without affecting consciousness.
Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Preference (PROPr) score
Time frame: Through 8 weeks after randomization
Change from baseline in orthostatic intolerance symptoms
Change in the following measures, all scored as worsened, no change, or improved from baseline: Sustained increased heart rate (HR) (\>= 30 beats per minute (bpm) for 20+ year old or \>= 40 bpm for \< 20 year old) from supine HR or an absolute HR \>= 120 bpm during the first 10 minutes of standing of the Active Stand Test Sustained decreased blood pressure (BP) (\>=20 mmHg in systolic pressure or \>=10 mmHg in diastolic pressure) during the first 10 minutes of standing of the Active Stand Test Any documented orthostatic intolerance (OI) symptoms (dizziness, blurry vision, fatigue, headache, and body pain) documented during the first 10 minutes of standing of the Active Stand Test
Time frame: Through 8 weeks after randomization
Change in Digit-Span WAIS-IV total age-corrected scaled score
Time frame: Through 8 weeks after randomization
Change in Functional Capacity Questionnaire (FUNCAP27) total mean score
Time frame: Through 8 weeks after randomization
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) total recall T-score
Time frame: Through 8 weeks after randomization
Change in HVLT-R retention % T-score
Time frame: Through 8 weeks after randomization
Change in Symbol Digit Modalities Test (SDMT) total T-score
Time frame: Through 8 weeks after randomization
Change in the Fatigue Severity Scale (FSS) mean item total score
Time frame: Through 8 weeks after randomization
Change in the HVLT-R recognition discrimination index T-score
Time frame: Through 8 weeks after randomization
Change in the Orthostatic Intolerance Questionnaire (OIQ) composite total score
Time frame: Through 8 weeks after randomization
Change in the total phonemic verbal fluency normed score
Time frame: Through 8 weeks after randomization
Change in the total semantic fluency normed score
Time frame: Through 8 weeks after randomization
Change in Trail Making Test (TMT) Part A total scaled score and Part B total scaled score
Time frame: Through 8 weeks after randomization
Incidence of New Onset Chronic Medical Conditions (NOCMCs)
Time frame: Through 26 weeks after randomization
Incidence of Solicited Adverse Events
Time frame: Through 4 days after SGB or Sham
Incidence of treatment-emergent Medically Attended Adverse Events (MAAEs)
Time frame: Through 26 weeks after randomization
Incidence of treatment-emergent serious adverse events (SAEs)
Time frame: Through 26 weeks after randomization
Incidence of treatment-emergent unsolicited Adverse Events
Time frame: Through 12 weeks after randomization
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2029, 28 months later.
Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 28 months is above that.
Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
National Institute of Allergy and Infectious Diseases (NIAID) →